Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

diaDexus moves CAD (coronary artery disease) risk test closer to the US:

This article was originally published in Clinica

  • News

Executive Summary

diaDexus is pushing ahead with efforts to market in the US its PLAC blood test for predicting coronary artery disease (CAD) risk, after submitting a 510(k) application for the product to the FDA. The test provides a quantitative measurement of lipoprotein-associated phospholipase A2, or Lp-PLA2, a marker believed to be a risk factor for coronary heart disease. Since a significant proportion of individuals who suffer a heart attack have no previous signs or symptoms of coronary heart disease, such as elevated cholesterol, there is clearly a need for additional tests to accurately identify those at risk, says Patrick Plewman, the San Francisco, California's firm's CEO.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

ORA’s Chief Says Without Additional Funding, Inspections Are In Jeopardy

News We’re Watching: Philips Settles Recall Fallout; FDA REdI, Townhalls, Approvals

ICER Debuts Clinical Trial Diversity Assessment Framework

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

See All
UsernamePublicRestriction

Register

MT061417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By